Drug combination shows promise for newly diagnosed blood cancer patients, study finds

Cell Therapy Summit EU CTS Europe The Leadership Gathering for Cell therapy Executives
98% Thyroid Disease Cured 100% Natural Herbs, with TGA, GMP, SGS. Thousands of recovery cases!
M ultiple Sclerosis Recovery for MS in China by herbal tea, massage, acupuncture.
Articles
Science News
Drug Combination Shows Promise for Newly Diagnosed Blood Cancer
Just In:
Brain Imaging Shows Video Game Aptitude
Patients, Study Finds
Science Video News
ScienceDaily (Dec. 11, 2010) — A new three-drug Ads by Google
combination used to treat the blood cancer multiple Heate d Che mo
myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer www .aldlife .org Holley Pharmaceuticals
Ocular Oncologists Inject Drug Into Eye To Starve See Also:
Urologists Use Optics, Chemistry to Catch Small Health & Medicine
Drug Discovery Conference
Molecular Biologists Devise Strategy To Starve New Sequencing Report
The Theory of Everything
Some physicists think the mind is at the heart American Society of HematologyAnnual Meeting and Exposition.
Reference
Related Stories
Hodgkin's lymphoma to deliver everything we expected and Aggressive Blood Cancer: Clinical Trial of
Clinical Research in AZ
Lenalidomide Plus Dexamethasone Followed
by Autologous Stem Cell Transplantation
(ASCT) in Multiple Myeloma (Dec. 7, 2010) — A
new transplantation technique, which uses a Head Covering - HeadBands
patient's own adult stem cells, has been a first-line program at the University of Michigan Comprehensive Cancer cotton silk wool hat for girl/women Fashion treatment for patients who are newly diagnosed with certain blood cancers. Multiple myeloma is a .
The study, which still is accruing participants, has enrolled 31 people to date. All patients responded to this combination, Multiple Myeloma Patients Experience High
measured by at least a 50 percent reduction of the disease, Response Rate With New 3-Drug Combination
Breaking News
and the disease was completely or nearly eliminated in a (Dec. 7, 2009) — A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly Responses were rapid, and the depth of response continued to effective regimen" in the treatment of patients newly improve with additional treatment. Of patients who completed diagnosed with multiple myeloma, a cancer of white eight cycles of therapy, more than two-thirds achieved a complete response, meaning they showed little or no signs of Three-Drug Combination 'Extremely Promising'
cancer. These response rates appear to be higher than those As First-Line Therapy For Multiple Myeloma
Akina Research
achieved by the best current regimens in newly diagnosed Polymers
bortezomib (Velcade) and two other drugs is After a median follow-up of six months, all patients were alive showing a very high response rate in patients newly with no progression of their cancer.
diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute . > read more Researchers found that the three-drug combination, called CRd, was well-tolerated, with few serious side effects. Most Multiple Myeloma Clinical Trial Shows Distinct
notably, peripheral neuropathy -- which is marked by Survival Benefit With Lower Dose Of Steroids
Migraine Resource
numbness or tingling of the fingers and toes and can cause (Dec. 13, 2007) — Results of Eastern Cooperative significant pain, depending on the severity -- was infrequent and Oncology Group Phase III clinical trial E4A03, for mild with this treatment. This side effect typically limits multiple myeloma show significantly better overall extended use of currently available multiple myeloma treatments and is often the reason patients discontinue a dexamethasone therapy . > read more In Othe r Ne ws .
New Therapeutic Options For Newly Diagnosed
The study also included patients who were eligible for a stem Multiple Myeloma Patients (Dec. 11, 2007) —
Pathology Cases
cell transplant. The researchers found that these patients were Mayo Clinic researchers have presented results of a able to remain on CRd treatment and achieved responses phase II trial of myeloma induction therapy -- a first similar to or better than those observed after a stem cell step therapy designed to reduce cancer cells transplant. This outcome delayed the need for a stem cell numbers -- with cyclophosphamide, bortezomib, .
"Newly diagnosed myeloma is most sensitive to treatment. A Ads by Google
great response in the initial phase of treatment is critical ECCO-the European
because it projects how long patients will remain in remission, Single Cell PCR
as well as their overall survival. Patients have a better chance of living longer if their response to initial treatment is better," says Jakubowiak, associate professor of internal medicine at LatinClin
Carfilzomib has recently emerged as an important drug in treatment of multiple myeloma. It has previously been tested as a single-agent in patients who have exhausted all available treatment options and in relapsed disease. Currently, a Phase PharmGenomics
III trial is ongoing looking at CRd compared with lenalidomide Anti-fungal remedy
and low dose dexamethasone alone for patients with relapsed Multiple myeloma statistics:
Renal Cell Carcinoma
20,180 Americans will be diagnosed with multiple myeloma Giffords doing well after weekend surgeries: this year and 10,650 will die from the disease, according to the Additional authors:
Dominik Dytfeld, M.D., Ph.D., Tara B. Anderson, Brian Copyright Reuters 2008. See Restrictions. Nordgren, Daniel Lebovic, M.D., Kent Griffith, Melissa Hill,Colleen Harvey, all from U-M; Sundar Jagannath, M.D., Mt.
Sinai Medical Center; David H. Vesole, M.D., Ph.D., Free Subscriptions
Hackensack University Medical Center; Keith Stockerl-Goldstein, M.D., and Ravi Vij, M.D., Washington University Get the latest science news with our free email School of Medicine, St. Louis; Akari Dollard, Dana Farber newsletters, updated daily and weekly. Or view Cancer Institute; Robert Ott and Susan L. Kelley, M.D., hourly updated newsfeeds in your RSS reader: Multiple Myeloma Research Consortium; Jennifer Barrickman, Celgene Corp.; and Michael Kauffman, M.D., Onyx Funding:
Feedback
Multiple Myeloma Research Consortium, Onyx Tell us what you think of ScienceDaily -- we Pharmaceuticals Inc., Celgene Corporation and the U-M welcome both positive and negative comments.
Have any problems using the site? Questions? Story Source:
The above story is reprinted (with editorial adaptations by
ScienceDaily staff) from materials provided by University of
Michigan Health System.
Need to cite this story in your essay, paper, or report? Use University of Michigan Health System (2010,December 11). Drug combination shows promise for newly diagnosed blood cancerpatients, study finds. ScienceDaily. RetrievedJanuary 18, 2011, from Note: If no author is given, the source is cited instead. Disclaimer: This article is not intended to provide medical
advice, diagnosis or treatment. Views expressed here do not
necessarily reflect those of ScienceDaily or its staff.
Search ScienceDaily
Number of stories in archives: 96,676 Enter a keyword or phrase to search ScienceDaily's archives for related news topics, the latest news stories, reference articles, science videos, images, and books.
About ScienceDaily® | Editorial Staff | Awards & Reviews | Contribute News | Advertise With Us | Privacy Policy | Terms of Use Copyright 1995-2010 ScienceDaily LLC — All rights reserved — Contact: Note: This web site is not intended to provide medical advice, diagnosis or treatment. Part of the iVillage Your Total Health Network

Source: http://www.ipi.ir/DataInfo%5CEnglish%5CDrug%20Combination%20Shows%20Promise%20for%20Newly%20Diagnosed%20Blood%20Cancer%20Patients,%20Study%20Finds.pdf